Global Scopolamine
Global Scopolamine

Scopolamine Comprehensive Study by Type (Scopolamine Butylbromide, Scopolamine Hydrobromide, Scopolamine Base), Application (Oral, Injection, Patches), Form (Tablet, Syrup), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Side Effects (Fatigue, Dry mouth, Diarrhea, Pharyngitis, Agitation, Others) Players and Region - Global Market Outlook to 2025

Scopolamine Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Sep 2020 Edition 208 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scopolamine Market Scope
Scopolamine is an alkaloid drug extracted from a plant called henbane used to treat nausea and motion sickness and to further dilate the pupil during ophthalmic procedures. Scopolamine belongs to a class of drugs called anticholinergics. It blocks the activity of the neurotransmitter acetylcholine, which stimulates the part of the brain that causes nausea and vomiting, involuntary muscle movements in the lungs, gastrointestinal and urinary tracts. Scopolamine reduces the secretion of certain organs in the body, such as the stomach and intestines. Scopolamine also decreases nerve signals that make your stomach vomit. Scopolamine is used to prevent nausea and vomiting from motion sickness or anesthesia during surgery. Scopolamine is also used to treat certain stomach or intestinal problems, muscle cramps, and Parkinson's-like conditions. An overdose of scopolamine can be fatal. Overdose symptoms may include fever, warmth, vomiting, restlessness or excitement, confusion, hallucinations, weak or shallow breathing, or fits (convulsions). This medicine can cause blurred vision, thinking, and reactions. Scopolamine can reduce sweating, making it more prone to heatstroke. Scopolamine can also dilate the pupils and make the eyes more sensitive to light.

The market study is being classified by Type (Scopolamine Butylbromide, Scopolamine Hydrobromide and Scopolamine Base), by Application (Oral, Injection and Patches) and major geographies with country level break-up.

The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that Asia Pacific Players will contribute to the maximum growth of Global Scopolamine market throughout the predicted period.

Baxter International Inc. (United States), GlaxoSmithKline plc. Novartis AG (United Kingdom), Perrigo Company plc. (Dublin), Caleb Pharmaceuticals, Inc. (Taiwan), Myungmoon Pharma Co. Ltd. (South Korea), Alchem International (India), Phytex Australia (Australia), Centroflora Group (Brazil), Alkaloids of Australia (Australia) and Fine Chemicals Corporation (South Africa) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Vista Medical Ltd. (Canada) and Ohmatex ApS (Denmark).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Scopolamine market by Type, Application and Region.

On the basis of geography, the market of Scopolamine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).


Prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: antihistamines such as meclizine (Antivert, Bonine, others); medications for anxiety, irritable bowel disease, motion sickness, pain, Parkinson's disease, seizures or urinary problems; muscle relaxants; sedatives; sleeping pills; tranquilizers; or tricyclic antidepressants such as desipramine (Norpramin), clomipramine (Anafranil), imipramine (Tofranil), and trimipramine (Surmontil) Many other medications may also interact with scopolamine patch, so be sure to tell the doctor about all the medications that are being taken, even those that do not appear.

Market Trend
  • Growth in the Number of Travelers around the Globe
  • The Growing Medical Tourism for Surgeries

Market Drivers
  • Increasing Prevalence of Motion Sickness
  • Increasing Number of Population Suffering From Stress and Anxiety Disorder
  • Increased Expenditure on Healthcare

Opportunities
  • Increasing Consumption of Unhealthy Food Leading To Obesity and Other Stomach Related Infections
  • Diagnostic or Staging Test in the Evaluation of the Cholinergic System

Restraints
  • Stringent Regulations against the Manufacturing and Marketing of the Drug

Challenges
  • Abuse Of Drugs in Various Regions Illegally


Key Target Audience
Manufacturers of Scopolamine, Suppliers and Distributors of Scopolamine, End-Users, Potential Investors, Market Research Firms and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Scopolamine Butylbromide
  • Scopolamine Hydrobromide
  • Scopolamine Base
By Application
  • Oral
  • Injection
  • Patches
By Form
  • Tablet
  • Syrup

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Side Effects
  • Fatigue
  • Dry mouth
  • Diarrhea
  • Pharyngitis
  • Agitation
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Motion Sickness
      • 3.2.2. Increasing Number of Population Suffering From Stress and Anxiety Disorder
      • 3.2.3. Increased Expenditure on Healthcare
    • 3.3. Market Challenges
      • 3.3.1. Abuse Of Drugs in Various Regions Illegally
    • 3.4. Market Trends
      • 3.4.1. Growth in the Number of Travelers around the Globe
      • 3.4.2. The Growing Medical Tourism for Surgeries
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Scopolamine, by Type, Application, Form, Distribution Channel, Side Effects and Region (value, volume and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Scopolamine (Value)
      • 5.2.1. Global Scopolamine by: Type (Value)
        • 5.2.1.1. Scopolamine Butylbromide
        • 5.2.1.2. Scopolamine Hydrobromide
        • 5.2.1.3. Scopolamine Base
      • 5.2.2. Global Scopolamine by: Application (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Injection
        • 5.2.2.3. Patches
      • 5.2.3. Global Scopolamine by: Form (Value)
        • 5.2.3.1. Tablet
        • 5.2.3.2. Syrup
      • 5.2.4. Global Scopolamine by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacies
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Online Pharmacies
      • 5.2.5. Global Scopolamine by: Side Effects (Value)
        • 5.2.5.1. Fatigue
        • 5.2.5.2. Dry mouth
        • 5.2.5.3. Diarrhea
        • 5.2.5.4. Pharyngitis
        • 5.2.5.5. Agitation
        • 5.2.5.6. Others
      • 5.2.6. Global Scopolamine Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Scopolamine (Volume)
      • 5.3.1. Global Scopolamine by: Type (Volume)
        • 5.3.1.1. Scopolamine Butylbromide
        • 5.3.1.2. Scopolamine Hydrobromide
        • 5.3.1.3. Scopolamine Base
      • 5.3.2. Global Scopolamine by: Application (Volume)
        • 5.3.2.1. Oral
        • 5.3.2.2. Injection
        • 5.3.2.3. Patches
      • 5.3.3. Global Scopolamine by: Form (Volume)
        • 5.3.3.1. Tablet
        • 5.3.3.2. Syrup
      • 5.3.4. Global Scopolamine by: Distribution Channel (Volume)
        • 5.3.4.1. Hospital Pharmacies
        • 5.3.4.2. Retail Pharmacies
        • 5.3.4.3. Online Pharmacies
      • 5.3.5. Global Scopolamine by: Side Effects (Volume)
        • 5.3.5.1. Fatigue
        • 5.3.5.2. Dry mouth
        • 5.3.5.3. Diarrhea
        • 5.3.5.4. Pharyngitis
        • 5.3.5.5. Agitation
        • 5.3.5.6. Others
      • 5.3.6. Global Scopolamine Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Scopolamine (Price)
      • 5.4.1. Global Scopolamine by: Type (Price)
  • 6. Scopolamine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Baxter International Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline plc. Novartis AG (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Perrigo Company plc. (Dublin)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Caleb Pharmaceuticals, Inc. (Taiwan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Myungmoon Pharma Co. Ltd. (South Korea)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Alchem International (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Phytex Australia (Australia)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Centroflora Group (Brazil)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Alkaloids of Australia (Australia)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Fine Chemicals Corporation (South Africa)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Scopolamine Sale, by Type, Application, Form, Distribution Channel, Side Effects and Region (value, volume and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Scopolamine (Value)
      • 7.2.1. Global Scopolamine by: Type (Value)
        • 7.2.1.1. Scopolamine Butylbromide
        • 7.2.1.2. Scopolamine Hydrobromide
        • 7.2.1.3. Scopolamine Base
      • 7.2.2. Global Scopolamine by: Application (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Injection
        • 7.2.2.3. Patches
      • 7.2.3. Global Scopolamine by: Form (Value)
        • 7.2.3.1. Tablet
        • 7.2.3.2. Syrup
      • 7.2.4. Global Scopolamine by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacies
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Online Pharmacies
      • 7.2.5. Global Scopolamine by: Side Effects (Value)
        • 7.2.5.1. Fatigue
        • 7.2.5.2. Dry mouth
        • 7.2.5.3. Diarrhea
        • 7.2.5.4. Pharyngitis
        • 7.2.5.5. Agitation
        • 7.2.5.6. Others
      • 7.2.6. Global Scopolamine Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Scopolamine (Volume)
      • 7.3.1. Global Scopolamine by: Type (Volume)
        • 7.3.1.1. Scopolamine Butylbromide
        • 7.3.1.2. Scopolamine Hydrobromide
        • 7.3.1.3. Scopolamine Base
      • 7.3.2. Global Scopolamine by: Application (Volume)
        • 7.3.2.1. Oral
        • 7.3.2.2. Injection
        • 7.3.2.3. Patches
      • 7.3.3. Global Scopolamine by: Form (Volume)
        • 7.3.3.1. Tablet
        • 7.3.3.2. Syrup
      • 7.3.4. Global Scopolamine by: Distribution Channel (Volume)
        • 7.3.4.1. Hospital Pharmacies
        • 7.3.4.2. Retail Pharmacies
        • 7.3.4.3. Online Pharmacies
      • 7.3.5. Global Scopolamine by: Side Effects (Volume)
        • 7.3.5.1. Fatigue
        • 7.3.5.2. Dry mouth
        • 7.3.5.3. Diarrhea
        • 7.3.5.4. Pharyngitis
        • 7.3.5.5. Agitation
        • 7.3.5.6. Others
      • 7.3.6. Global Scopolamine Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Scopolamine (Price)
      • 7.4.1. Global Scopolamine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Scopolamine: by Type(USD Million)
  • Table 2. Scopolamine Scopolamine Butylbromide , by Region USD Million (2014-2019)
  • Table 3. Scopolamine Scopolamine Hydrobromide , by Region USD Million (2014-2019)
  • Table 4. Scopolamine Scopolamine Base , by Region USD Million (2014-2019)
  • Table 5. Scopolamine: by Application(USD Million)
  • Table 6. Scopolamine Oral , by Region USD Million (2014-2019)
  • Table 7. Scopolamine Injection , by Region USD Million (2014-2019)
  • Table 8. Scopolamine Patches , by Region USD Million (2014-2019)
  • Table 9. Scopolamine: by Form(USD Million)
  • Table 10. Scopolamine Tablet , by Region USD Million (2014-2019)
  • Table 11. Scopolamine Syrup , by Region USD Million (2014-2019)
  • Table 12. Scopolamine: by Distribution Channel(USD Million)
  • Table 13. Scopolamine Hospital Pharmacies , by Region USD Million (2014-2019)
  • Table 14. Scopolamine Retail Pharmacies , by Region USD Million (2014-2019)
  • Table 15. Scopolamine Online Pharmacies , by Region USD Million (2014-2019)
  • Table 16. Scopolamine: by Side Effects(USD Million)
  • Table 17. Scopolamine Fatigue , by Region USD Million (2014-2019)
  • Table 18. Scopolamine Dry mouth , by Region USD Million (2014-2019)
  • Table 19. Scopolamine Diarrhea , by Region USD Million (2014-2019)
  • Table 20. Scopolamine Pharyngitis , by Region USD Million (2014-2019)
  • Table 21. Scopolamine Agitation , by Region USD Million (2014-2019)
  • Table 22. Scopolamine Others , by Region USD Million (2014-2019)
  • Table 23. South America Scopolamine, by Country USD Million (2014-2019)
  • Table 24. South America Scopolamine, by Type USD Million (2014-2019)
  • Table 25. South America Scopolamine, by Application USD Million (2014-2019)
  • Table 26. South America Scopolamine, by Form USD Million (2014-2019)
  • Table 27. South America Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 28. South America Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 29. Brazil Scopolamine, by Type USD Million (2014-2019)
  • Table 30. Brazil Scopolamine, by Application USD Million (2014-2019)
  • Table 31. Brazil Scopolamine, by Form USD Million (2014-2019)
  • Table 32. Brazil Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 33. Brazil Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 34. Argentina Scopolamine, by Type USD Million (2014-2019)
  • Table 35. Argentina Scopolamine, by Application USD Million (2014-2019)
  • Table 36. Argentina Scopolamine, by Form USD Million (2014-2019)
  • Table 37. Argentina Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 38. Argentina Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 39. Rest of South America Scopolamine, by Type USD Million (2014-2019)
  • Table 40. Rest of South America Scopolamine, by Application USD Million (2014-2019)
  • Table 41. Rest of South America Scopolamine, by Form USD Million (2014-2019)
  • Table 42. Rest of South America Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 43. Rest of South America Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 44. Asia Pacific Scopolamine, by Country USD Million (2014-2019)
  • Table 45. Asia Pacific Scopolamine, by Type USD Million (2014-2019)
  • Table 46. Asia Pacific Scopolamine, by Application USD Million (2014-2019)
  • Table 47. Asia Pacific Scopolamine, by Form USD Million (2014-2019)
  • Table 48. Asia Pacific Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 49. Asia Pacific Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 50. China Scopolamine, by Type USD Million (2014-2019)
  • Table 51. China Scopolamine, by Application USD Million (2014-2019)
  • Table 52. China Scopolamine, by Form USD Million (2014-2019)
  • Table 53. China Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 54. China Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 55. Japan Scopolamine, by Type USD Million (2014-2019)
  • Table 56. Japan Scopolamine, by Application USD Million (2014-2019)
  • Table 57. Japan Scopolamine, by Form USD Million (2014-2019)
  • Table 58. Japan Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 59. Japan Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 60. India Scopolamine, by Type USD Million (2014-2019)
  • Table 61. India Scopolamine, by Application USD Million (2014-2019)
  • Table 62. India Scopolamine, by Form USD Million (2014-2019)
  • Table 63. India Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 64. India Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 65. South Korea Scopolamine, by Type USD Million (2014-2019)
  • Table 66. South Korea Scopolamine, by Application USD Million (2014-2019)
  • Table 67. South Korea Scopolamine, by Form USD Million (2014-2019)
  • Table 68. South Korea Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 69. South Korea Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 70. Taiwan Scopolamine, by Type USD Million (2014-2019)
  • Table 71. Taiwan Scopolamine, by Application USD Million (2014-2019)
  • Table 72. Taiwan Scopolamine, by Form USD Million (2014-2019)
  • Table 73. Taiwan Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 74. Taiwan Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 75. Australia Scopolamine, by Type USD Million (2014-2019)
  • Table 76. Australia Scopolamine, by Application USD Million (2014-2019)
  • Table 77. Australia Scopolamine, by Form USD Million (2014-2019)
  • Table 78. Australia Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 79. Australia Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 80. Rest of Asia-Pacific Scopolamine, by Type USD Million (2014-2019)
  • Table 81. Rest of Asia-Pacific Scopolamine, by Application USD Million (2014-2019)
  • Table 82. Rest of Asia-Pacific Scopolamine, by Form USD Million (2014-2019)
  • Table 83. Rest of Asia-Pacific Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 84. Rest of Asia-Pacific Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 85. Europe Scopolamine, by Country USD Million (2014-2019)
  • Table 86. Europe Scopolamine, by Type USD Million (2014-2019)
  • Table 87. Europe Scopolamine, by Application USD Million (2014-2019)
  • Table 88. Europe Scopolamine, by Form USD Million (2014-2019)
  • Table 89. Europe Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 90. Europe Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 91. Germany Scopolamine, by Type USD Million (2014-2019)
  • Table 92. Germany Scopolamine, by Application USD Million (2014-2019)
  • Table 93. Germany Scopolamine, by Form USD Million (2014-2019)
  • Table 94. Germany Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 95. Germany Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 96. France Scopolamine, by Type USD Million (2014-2019)
  • Table 97. France Scopolamine, by Application USD Million (2014-2019)
  • Table 98. France Scopolamine, by Form USD Million (2014-2019)
  • Table 99. France Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 100. France Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 101. Italy Scopolamine, by Type USD Million (2014-2019)
  • Table 102. Italy Scopolamine, by Application USD Million (2014-2019)
  • Table 103. Italy Scopolamine, by Form USD Million (2014-2019)
  • Table 104. Italy Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 105. Italy Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 106. United Kingdom Scopolamine, by Type USD Million (2014-2019)
  • Table 107. United Kingdom Scopolamine, by Application USD Million (2014-2019)
  • Table 108. United Kingdom Scopolamine, by Form USD Million (2014-2019)
  • Table 109. United Kingdom Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 110. United Kingdom Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 111. Netherlands Scopolamine, by Type USD Million (2014-2019)
  • Table 112. Netherlands Scopolamine, by Application USD Million (2014-2019)
  • Table 113. Netherlands Scopolamine, by Form USD Million (2014-2019)
  • Table 114. Netherlands Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 115. Netherlands Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 116. Rest of Europe Scopolamine, by Type USD Million (2014-2019)
  • Table 117. Rest of Europe Scopolamine, by Application USD Million (2014-2019)
  • Table 118. Rest of Europe Scopolamine, by Form USD Million (2014-2019)
  • Table 119. Rest of Europe Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 120. Rest of Europe Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 121. MEA Scopolamine, by Country USD Million (2014-2019)
  • Table 122. MEA Scopolamine, by Type USD Million (2014-2019)
  • Table 123. MEA Scopolamine, by Application USD Million (2014-2019)
  • Table 124. MEA Scopolamine, by Form USD Million (2014-2019)
  • Table 125. MEA Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 126. MEA Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 127. Middle East Scopolamine, by Type USD Million (2014-2019)
  • Table 128. Middle East Scopolamine, by Application USD Million (2014-2019)
  • Table 129. Middle East Scopolamine, by Form USD Million (2014-2019)
  • Table 130. Middle East Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 131. Middle East Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 132. Africa Scopolamine, by Type USD Million (2014-2019)
  • Table 133. Africa Scopolamine, by Application USD Million (2014-2019)
  • Table 134. Africa Scopolamine, by Form USD Million (2014-2019)
  • Table 135. Africa Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 136. Africa Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 137. North America Scopolamine, by Country USD Million (2014-2019)
  • Table 138. North America Scopolamine, by Type USD Million (2014-2019)
  • Table 139. North America Scopolamine, by Application USD Million (2014-2019)
  • Table 140. North America Scopolamine, by Form USD Million (2014-2019)
  • Table 141. North America Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 142. North America Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 143. United States Scopolamine, by Type USD Million (2014-2019)
  • Table 144. United States Scopolamine, by Application USD Million (2014-2019)
  • Table 145. United States Scopolamine, by Form USD Million (2014-2019)
  • Table 146. United States Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 147. United States Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 148. Canada Scopolamine, by Type USD Million (2014-2019)
  • Table 149. Canada Scopolamine, by Application USD Million (2014-2019)
  • Table 150. Canada Scopolamine, by Form USD Million (2014-2019)
  • Table 151. Canada Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 152. Canada Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 153. Mexico Scopolamine, by Type USD Million (2014-2019)
  • Table 154. Mexico Scopolamine, by Application USD Million (2014-2019)
  • Table 155. Mexico Scopolamine, by Form USD Million (2014-2019)
  • Table 156. Mexico Scopolamine, by Distribution Channel USD Million (2014-2019)
  • Table 157. Mexico Scopolamine, by Side Effects USD Million (2014-2019)
  • Table 158. Scopolamine Sales: by Type(K Tons)
  • Table 159. Scopolamine Sales Scopolamine Butylbromide , by Region K Tons (2014-2019)
  • Table 160. Scopolamine Sales Scopolamine Hydrobromide , by Region K Tons (2014-2019)
  • Table 161. Scopolamine Sales Scopolamine Base , by Region K Tons (2014-2019)
  • Table 162. Scopolamine Sales: by Application(K Tons)
  • Table 163. Scopolamine Sales Oral , by Region K Tons (2014-2019)
  • Table 164. Scopolamine Sales Injection , by Region K Tons (2014-2019)
  • Table 165. Scopolamine Sales Patches , by Region K Tons (2014-2019)
  • Table 166. Scopolamine Sales: by Form(K Tons)
  • Table 167. Scopolamine Sales Tablet , by Region K Tons (2014-2019)
  • Table 168. Scopolamine Sales Syrup , by Region K Tons (2014-2019)
  • Table 169. Scopolamine Sales: by Distribution Channel(K Tons)
  • Table 170. Scopolamine Sales Hospital Pharmacies , by Region K Tons (2014-2019)
  • Table 171. Scopolamine Sales Retail Pharmacies , by Region K Tons (2014-2019)
  • Table 172. Scopolamine Sales Online Pharmacies , by Region K Tons (2014-2019)
  • Table 173. Scopolamine Sales: by Side Effects(K Tons)
  • Table 174. Scopolamine Sales Fatigue , by Region K Tons (2014-2019)
  • Table 175. Scopolamine Sales Dry mouth , by Region K Tons (2014-2019)
  • Table 176. Scopolamine Sales Diarrhea , by Region K Tons (2014-2019)
  • Table 177. Scopolamine Sales Pharyngitis , by Region K Tons (2014-2019)
  • Table 178. Scopolamine Sales Agitation , by Region K Tons (2014-2019)
  • Table 179. Scopolamine Sales Others , by Region K Tons (2014-2019)
  • Table 180. South America Scopolamine Sales, by Country K Tons (2014-2019)
  • Table 181. South America Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 182. South America Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 183. South America Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 184. South America Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 185. South America Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 186. Brazil Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 187. Brazil Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 188. Brazil Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 189. Brazil Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 190. Brazil Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 191. Argentina Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 192. Argentina Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 193. Argentina Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 194. Argentina Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 195. Argentina Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 196. Rest of South America Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 197. Rest of South America Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 198. Rest of South America Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 199. Rest of South America Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 200. Rest of South America Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 201. Asia Pacific Scopolamine Sales, by Country K Tons (2014-2019)
  • Table 202. Asia Pacific Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 203. Asia Pacific Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 204. Asia Pacific Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 205. Asia Pacific Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 206. Asia Pacific Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 207. China Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 208. China Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 209. China Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 210. China Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 211. China Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 212. Japan Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 213. Japan Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 214. Japan Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 215. Japan Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 216. Japan Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 217. India Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 218. India Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 219. India Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 220. India Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 221. India Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 222. South Korea Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 223. South Korea Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 224. South Korea Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 225. South Korea Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 226. South Korea Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 227. Taiwan Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 228. Taiwan Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 229. Taiwan Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 230. Taiwan Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 231. Taiwan Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 232. Australia Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 233. Australia Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 234. Australia Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 235. Australia Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 236. Australia Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 237. Rest of Asia-Pacific Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 238. Rest of Asia-Pacific Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 239. Rest of Asia-Pacific Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 240. Rest of Asia-Pacific Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 241. Rest of Asia-Pacific Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 242. Europe Scopolamine Sales, by Country K Tons (2014-2019)
  • Table 243. Europe Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 244. Europe Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 245. Europe Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 246. Europe Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 247. Europe Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 248. Germany Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 249. Germany Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 250. Germany Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 251. Germany Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 252. Germany Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 253. France Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 254. France Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 255. France Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 256. France Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 257. France Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 258. Italy Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 259. Italy Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 260. Italy Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 261. Italy Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 262. Italy Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 263. United Kingdom Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 264. United Kingdom Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 265. United Kingdom Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 266. United Kingdom Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 267. United Kingdom Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 268. Netherlands Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 269. Netherlands Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 270. Netherlands Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 271. Netherlands Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 272. Netherlands Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 273. Rest of Europe Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 274. Rest of Europe Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 275. Rest of Europe Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 276. Rest of Europe Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 277. Rest of Europe Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 278. MEA Scopolamine Sales, by Country K Tons (2014-2019)
  • Table 279. MEA Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 280. MEA Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 281. MEA Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 282. MEA Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 283. MEA Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 284. Middle East Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 285. Middle East Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 286. Middle East Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 287. Middle East Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 288. Middle East Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 289. Africa Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 290. Africa Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 291. Africa Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 292. Africa Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 293. Africa Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 294. North America Scopolamine Sales, by Country K Tons (2014-2019)
  • Table 295. North America Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 296. North America Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 297. North America Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 298. North America Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 299. North America Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 300. United States Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 301. United States Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 302. United States Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 303. United States Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 304. United States Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 305. Canada Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 306. Canada Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 307. Canada Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 308. Canada Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 309. Canada Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 310. Mexico Scopolamine Sales, by Type K Tons (2014-2019)
  • Table 311. Mexico Scopolamine Sales, by Application K Tons (2014-2019)
  • Table 312. Mexico Scopolamine Sales, by Form K Tons (2014-2019)
  • Table 313. Mexico Scopolamine Sales, by Distribution Channel K Tons (2014-2019)
  • Table 314. Mexico Scopolamine Sales, by Side Effects K Tons (2014-2019)
  • Table 315. Scopolamine: by Type(USD/Units)
  • Table 316. Company Basic Information, Sales Area and Its Competitors
  • Table 317. Company Basic Information, Sales Area and Its Competitors
  • Table 318. Company Basic Information, Sales Area and Its Competitors
  • Table 319. Company Basic Information, Sales Area and Its Competitors
  • Table 320. Company Basic Information, Sales Area and Its Competitors
  • Table 321. Company Basic Information, Sales Area and Its Competitors
  • Table 322. Company Basic Information, Sales Area and Its Competitors
  • Table 323. Company Basic Information, Sales Area and Its Competitors
  • Table 324. Company Basic Information, Sales Area and Its Competitors
  • Table 325. Company Basic Information, Sales Area and Its Competitors
  • Table 326. Scopolamine: by Type(USD Million)
  • Table 327. Scopolamine Scopolamine Butylbromide , by Region USD Million (2020-2025)
  • Table 328. Scopolamine Scopolamine Hydrobromide , by Region USD Million (2020-2025)
  • Table 329. Scopolamine Scopolamine Base , by Region USD Million (2020-2025)
  • Table 330. Scopolamine: by Application(USD Million)
  • Table 331. Scopolamine Oral , by Region USD Million (2020-2025)
  • Table 332. Scopolamine Injection , by Region USD Million (2020-2025)
  • Table 333. Scopolamine Patches , by Region USD Million (2020-2025)
  • Table 334. Scopolamine: by Form(USD Million)
  • Table 335. Scopolamine Tablet , by Region USD Million (2020-2025)
  • Table 336. Scopolamine Syrup , by Region USD Million (2020-2025)
  • Table 337. Scopolamine: by Distribution Channel(USD Million)
  • Table 338. Scopolamine Hospital Pharmacies , by Region USD Million (2020-2025)
  • Table 339. Scopolamine Retail Pharmacies , by Region USD Million (2020-2025)
  • Table 340. Scopolamine Online Pharmacies , by Region USD Million (2020-2025)
  • Table 341. Scopolamine: by Side Effects(USD Million)
  • Table 342. Scopolamine Fatigue , by Region USD Million (2020-2025)
  • Table 343. Scopolamine Dry mouth , by Region USD Million (2020-2025)
  • Table 344. Scopolamine Diarrhea , by Region USD Million (2020-2025)
  • Table 345. Scopolamine Pharyngitis , by Region USD Million (2020-2025)
  • Table 346. Scopolamine Agitation , by Region USD Million (2020-2025)
  • Table 347. Scopolamine Others , by Region USD Million (2020-2025)
  • Table 348. South America Scopolamine, by Country USD Million (2020-2025)
  • Table 349. South America Scopolamine, by Type USD Million (2020-2025)
  • Table 350. South America Scopolamine, by Application USD Million (2020-2025)
  • Table 351. South America Scopolamine, by Form USD Million (2020-2025)
  • Table 352. South America Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 353. South America Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 354. Brazil Scopolamine, by Type USD Million (2020-2025)
  • Table 355. Brazil Scopolamine, by Application USD Million (2020-2025)
  • Table 356. Brazil Scopolamine, by Form USD Million (2020-2025)
  • Table 357. Brazil Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 358. Brazil Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 359. Argentina Scopolamine, by Type USD Million (2020-2025)
  • Table 360. Argentina Scopolamine, by Application USD Million (2020-2025)
  • Table 361. Argentina Scopolamine, by Form USD Million (2020-2025)
  • Table 362. Argentina Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 363. Argentina Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 364. Rest of South America Scopolamine, by Type USD Million (2020-2025)
  • Table 365. Rest of South America Scopolamine, by Application USD Million (2020-2025)
  • Table 366. Rest of South America Scopolamine, by Form USD Million (2020-2025)
  • Table 367. Rest of South America Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 368. Rest of South America Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 369. Asia Pacific Scopolamine, by Country USD Million (2020-2025)
  • Table 370. Asia Pacific Scopolamine, by Type USD Million (2020-2025)
  • Table 371. Asia Pacific Scopolamine, by Application USD Million (2020-2025)
  • Table 372. Asia Pacific Scopolamine, by Form USD Million (2020-2025)
  • Table 373. Asia Pacific Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 374. Asia Pacific Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 375. China Scopolamine, by Type USD Million (2020-2025)
  • Table 376. China Scopolamine, by Application USD Million (2020-2025)
  • Table 377. China Scopolamine, by Form USD Million (2020-2025)
  • Table 378. China Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 379. China Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 380. Japan Scopolamine, by Type USD Million (2020-2025)
  • Table 381. Japan Scopolamine, by Application USD Million (2020-2025)
  • Table 382. Japan Scopolamine, by Form USD Million (2020-2025)
  • Table 383. Japan Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 384. Japan Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 385. India Scopolamine, by Type USD Million (2020-2025)
  • Table 386. India Scopolamine, by Application USD Million (2020-2025)
  • Table 387. India Scopolamine, by Form USD Million (2020-2025)
  • Table 388. India Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 389. India Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 390. South Korea Scopolamine, by Type USD Million (2020-2025)
  • Table 391. South Korea Scopolamine, by Application USD Million (2020-2025)
  • Table 392. South Korea Scopolamine, by Form USD Million (2020-2025)
  • Table 393. South Korea Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 394. South Korea Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 395. Taiwan Scopolamine, by Type USD Million (2020-2025)
  • Table 396. Taiwan Scopolamine, by Application USD Million (2020-2025)
  • Table 397. Taiwan Scopolamine, by Form USD Million (2020-2025)
  • Table 398. Taiwan Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 399. Taiwan Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 400. Australia Scopolamine, by Type USD Million (2020-2025)
  • Table 401. Australia Scopolamine, by Application USD Million (2020-2025)
  • Table 402. Australia Scopolamine, by Form USD Million (2020-2025)
  • Table 403. Australia Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 404. Australia Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 405. Rest of Asia-Pacific Scopolamine, by Type USD Million (2020-2025)
  • Table 406. Rest of Asia-Pacific Scopolamine, by Application USD Million (2020-2025)
  • Table 407. Rest of Asia-Pacific Scopolamine, by Form USD Million (2020-2025)
  • Table 408. Rest of Asia-Pacific Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 409. Rest of Asia-Pacific Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 410. Europe Scopolamine, by Country USD Million (2020-2025)
  • Table 411. Europe Scopolamine, by Type USD Million (2020-2025)
  • Table 412. Europe Scopolamine, by Application USD Million (2020-2025)
  • Table 413. Europe Scopolamine, by Form USD Million (2020-2025)
  • Table 414. Europe Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 415. Europe Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 416. Germany Scopolamine, by Type USD Million (2020-2025)
  • Table 417. Germany Scopolamine, by Application USD Million (2020-2025)
  • Table 418. Germany Scopolamine, by Form USD Million (2020-2025)
  • Table 419. Germany Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 420. Germany Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 421. France Scopolamine, by Type USD Million (2020-2025)
  • Table 422. France Scopolamine, by Application USD Million (2020-2025)
  • Table 423. France Scopolamine, by Form USD Million (2020-2025)
  • Table 424. France Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 425. France Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 426. Italy Scopolamine, by Type USD Million (2020-2025)
  • Table 427. Italy Scopolamine, by Application USD Million (2020-2025)
  • Table 428. Italy Scopolamine, by Form USD Million (2020-2025)
  • Table 429. Italy Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 430. Italy Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 431. United Kingdom Scopolamine, by Type USD Million (2020-2025)
  • Table 432. United Kingdom Scopolamine, by Application USD Million (2020-2025)
  • Table 433. United Kingdom Scopolamine, by Form USD Million (2020-2025)
  • Table 434. United Kingdom Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 435. United Kingdom Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 436. Netherlands Scopolamine, by Type USD Million (2020-2025)
  • Table 437. Netherlands Scopolamine, by Application USD Million (2020-2025)
  • Table 438. Netherlands Scopolamine, by Form USD Million (2020-2025)
  • Table 439. Netherlands Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 440. Netherlands Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 441. Rest of Europe Scopolamine, by Type USD Million (2020-2025)
  • Table 442. Rest of Europe Scopolamine, by Application USD Million (2020-2025)
  • Table 443. Rest of Europe Scopolamine, by Form USD Million (2020-2025)
  • Table 444. Rest of Europe Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 445. Rest of Europe Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 446. MEA Scopolamine, by Country USD Million (2020-2025)
  • Table 447. MEA Scopolamine, by Type USD Million (2020-2025)
  • Table 448. MEA Scopolamine, by Application USD Million (2020-2025)
  • Table 449. MEA Scopolamine, by Form USD Million (2020-2025)
  • Table 450. MEA Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 451. MEA Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 452. Middle East Scopolamine, by Type USD Million (2020-2025)
  • Table 453. Middle East Scopolamine, by Application USD Million (2020-2025)
  • Table 454. Middle East Scopolamine, by Form USD Million (2020-2025)
  • Table 455. Middle East Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 456. Middle East Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 457. Africa Scopolamine, by Type USD Million (2020-2025)
  • Table 458. Africa Scopolamine, by Application USD Million (2020-2025)
  • Table 459. Africa Scopolamine, by Form USD Million (2020-2025)
  • Table 460. Africa Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 461. Africa Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 462. North America Scopolamine, by Country USD Million (2020-2025)
  • Table 463. North America Scopolamine, by Type USD Million (2020-2025)
  • Table 464. North America Scopolamine, by Application USD Million (2020-2025)
  • Table 465. North America Scopolamine, by Form USD Million (2020-2025)
  • Table 466. North America Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 467. North America Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 468. United States Scopolamine, by Type USD Million (2020-2025)
  • Table 469. United States Scopolamine, by Application USD Million (2020-2025)
  • Table 470. United States Scopolamine, by Form USD Million (2020-2025)
  • Table 471. United States Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 472. United States Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 473. Canada Scopolamine, by Type USD Million (2020-2025)
  • Table 474. Canada Scopolamine, by Application USD Million (2020-2025)
  • Table 475. Canada Scopolamine, by Form USD Million (2020-2025)
  • Table 476. Canada Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 477. Canada Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 478. Mexico Scopolamine, by Type USD Million (2020-2025)
  • Table 479. Mexico Scopolamine, by Application USD Million (2020-2025)
  • Table 480. Mexico Scopolamine, by Form USD Million (2020-2025)
  • Table 481. Mexico Scopolamine, by Distribution Channel USD Million (2020-2025)
  • Table 482. Mexico Scopolamine, by Side Effects USD Million (2020-2025)
  • Table 483. Scopolamine Sales: by Type(K Tons)
  • Table 484. Scopolamine Sales Scopolamine Butylbromide , by Region K Tons (2020-2025)
  • Table 485. Scopolamine Sales Scopolamine Hydrobromide , by Region K Tons (2020-2025)
  • Table 486. Scopolamine Sales Scopolamine Base , by Region K Tons (2020-2025)
  • Table 487. Scopolamine Sales: by Application(K Tons)
  • Table 488. Scopolamine Sales Oral , by Region K Tons (2020-2025)
  • Table 489. Scopolamine Sales Injection , by Region K Tons (2020-2025)
  • Table 490. Scopolamine Sales Patches , by Region K Tons (2020-2025)
  • Table 491. Scopolamine Sales: by Form(K Tons)
  • Table 492. Scopolamine Sales Tablet , by Region K Tons (2020-2025)
  • Table 493. Scopolamine Sales Syrup , by Region K Tons (2020-2025)
  • Table 494. Scopolamine Sales: by Distribution Channel(K Tons)
  • Table 495. Scopolamine Sales Hospital Pharmacies , by Region K Tons (2020-2025)
  • Table 496. Scopolamine Sales Retail Pharmacies , by Region K Tons (2020-2025)
  • Table 497. Scopolamine Sales Online Pharmacies , by Region K Tons (2020-2025)
  • Table 498. Scopolamine Sales: by Side Effects(K Tons)
  • Table 499. Scopolamine Sales Fatigue , by Region K Tons (2020-2025)
  • Table 500. Scopolamine Sales Dry mouth , by Region K Tons (2020-2025)
  • Table 501. Scopolamine Sales Diarrhea , by Region K Tons (2020-2025)
  • Table 502. Scopolamine Sales Pharyngitis , by Region K Tons (2020-2025)
  • Table 503. Scopolamine Sales Agitation , by Region K Tons (2020-2025)
  • Table 504. Scopolamine Sales Others , by Region K Tons (2020-2025)
  • Table 505. South America Scopolamine Sales, by Country K Tons (2020-2025)
  • Table 506. South America Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 507. South America Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 508. South America Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 509. South America Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 510. South America Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 511. Brazil Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 512. Brazil Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 513. Brazil Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 514. Brazil Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 515. Brazil Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 516. Argentina Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 517. Argentina Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 518. Argentina Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 519. Argentina Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 520. Argentina Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 521. Rest of South America Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 522. Rest of South America Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 523. Rest of South America Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 524. Rest of South America Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 525. Rest of South America Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 526. Asia Pacific Scopolamine Sales, by Country K Tons (2020-2025)
  • Table 527. Asia Pacific Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 528. Asia Pacific Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 529. Asia Pacific Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 530. Asia Pacific Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 531. Asia Pacific Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 532. China Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 533. China Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 534. China Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 535. China Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 536. China Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 537. Japan Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 538. Japan Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 539. Japan Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 540. Japan Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 541. Japan Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 542. India Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 543. India Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 544. India Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 545. India Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 546. India Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 547. South Korea Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 548. South Korea Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 549. South Korea Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 550. South Korea Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 551. South Korea Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 552. Taiwan Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 553. Taiwan Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 554. Taiwan Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 555. Taiwan Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 556. Taiwan Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 557. Australia Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 558. Australia Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 559. Australia Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 560. Australia Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 561. Australia Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 562. Rest of Asia-Pacific Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 563. Rest of Asia-Pacific Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 564. Rest of Asia-Pacific Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 565. Rest of Asia-Pacific Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 566. Rest of Asia-Pacific Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 567. Europe Scopolamine Sales, by Country K Tons (2020-2025)
  • Table 568. Europe Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 569. Europe Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 570. Europe Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 571. Europe Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 572. Europe Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 573. Germany Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 574. Germany Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 575. Germany Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 576. Germany Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 577. Germany Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 578. France Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 579. France Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 580. France Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 581. France Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 582. France Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 583. Italy Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 584. Italy Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 585. Italy Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 586. Italy Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 587. Italy Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 588. United Kingdom Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 589. United Kingdom Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 590. United Kingdom Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 591. United Kingdom Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 592. United Kingdom Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 593. Netherlands Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 594. Netherlands Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 595. Netherlands Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 596. Netherlands Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 597. Netherlands Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 598. Rest of Europe Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 599. Rest of Europe Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 600. Rest of Europe Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 601. Rest of Europe Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 602. Rest of Europe Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 603. MEA Scopolamine Sales, by Country K Tons (2020-2025)
  • Table 604. MEA Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 605. MEA Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 606. MEA Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 607. MEA Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 608. MEA Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 609. Middle East Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 610. Middle East Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 611. Middle East Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 612. Middle East Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 613. Middle East Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 614. Africa Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 615. Africa Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 616. Africa Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 617. Africa Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 618. Africa Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 619. North America Scopolamine Sales, by Country K Tons (2020-2025)
  • Table 620. North America Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 621. North America Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 622. North America Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 623. North America Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 624. North America Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 625. United States Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 626. United States Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 627. United States Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 628. United States Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 629. United States Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 630. Canada Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 631. Canada Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 632. Canada Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 633. Canada Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 634. Canada Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 635. Mexico Scopolamine Sales, by Type K Tons (2020-2025)
  • Table 636. Mexico Scopolamine Sales, by Application K Tons (2020-2025)
  • Table 637. Mexico Scopolamine Sales, by Form K Tons (2020-2025)
  • Table 638. Mexico Scopolamine Sales, by Distribution Channel K Tons (2020-2025)
  • Table 639. Mexico Scopolamine Sales, by Side Effects K Tons (2020-2025)
  • Table 640. Scopolamine: by Type(USD/Units)
  • Table 641. Research Programs/Design for This Report
  • Table 642. Key Data Information from Secondary Sources
  • Table 643. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Scopolamine: by Type USD Million (2014-2019)
  • Figure 5. Global Scopolamine: by Application USD Million (2014-2019)
  • Figure 6. Global Scopolamine: by Form USD Million (2014-2019)
  • Figure 7. Global Scopolamine: by Distribution Channel USD Million (2014-2019)
  • Figure 8. Global Scopolamine: by Side Effects USD Million (2014-2019)
  • Figure 9. South America Scopolamine Share (%), by Country
  • Figure 10. Asia Pacific Scopolamine Share (%), by Country
  • Figure 11. Europe Scopolamine Share (%), by Country
  • Figure 12. MEA Scopolamine Share (%), by Country
  • Figure 13. North America Scopolamine Share (%), by Country
  • Figure 14. Global Scopolamine: by Type K Tons (2014-2019)
  • Figure 15. Global Scopolamine: by Application K Tons (2014-2019)
  • Figure 16. Global Scopolamine: by Form K Tons (2014-2019)
  • Figure 17. Global Scopolamine: by Distribution Channel K Tons (2014-2019)
  • Figure 18. Global Scopolamine: by Side Effects K Tons (2014-2019)
  • Figure 19. South America Scopolamine Share (%), by Country
  • Figure 20. Asia Pacific Scopolamine Share (%), by Country
  • Figure 21. Europe Scopolamine Share (%), by Country
  • Figure 22. MEA Scopolamine Share (%), by Country
  • Figure 23. North America Scopolamine Share (%), by Country
  • Figure 24. Global Scopolamine: by Type USD/Units (2014-2019)
  • Figure 25. Global Scopolamine share by Players 2019 (%)
  • Figure 26. Global Scopolamine share by Players (Top 3) 2019(%)
  • Figure 27. Global Scopolamine share by Players (Top 5) 2019(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. Baxter International Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Baxter International Inc. (United States) Revenue: by Geography 2019
  • Figure 31. GlaxoSmithKline plc. Novartis AG (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. GlaxoSmithKline plc. Novartis AG (United Kingdom) Revenue: by Geography 2019
  • Figure 33. Perrigo Company plc. (Dublin) Revenue, Net Income and Gross profit
  • Figure 34. Perrigo Company plc. (Dublin) Revenue: by Geography 2019
  • Figure 35. Caleb Pharmaceuticals, Inc. (Taiwan) Revenue, Net Income and Gross profit
  • Figure 36. Caleb Pharmaceuticals, Inc. (Taiwan) Revenue: by Geography 2019
  • Figure 37. Myungmoon Pharma Co. Ltd. (South Korea) Revenue, Net Income and Gross profit
  • Figure 38. Myungmoon Pharma Co. Ltd. (South Korea) Revenue: by Geography 2019
  • Figure 39. Alchem International (India) Revenue, Net Income and Gross profit
  • Figure 40. Alchem International (India) Revenue: by Geography 2019
  • Figure 41. Phytex Australia (Australia) Revenue, Net Income and Gross profit
  • Figure 42. Phytex Australia (Australia) Revenue: by Geography 2019
  • Figure 43. Centroflora Group (Brazil) Revenue, Net Income and Gross profit
  • Figure 44. Centroflora Group (Brazil) Revenue: by Geography 2019
  • Figure 45. Alkaloids of Australia (Australia) Revenue, Net Income and Gross profit
  • Figure 46. Alkaloids of Australia (Australia) Revenue: by Geography 2019
  • Figure 47. Fine Chemicals Corporation (South Africa) Revenue, Net Income and Gross profit
  • Figure 48. Fine Chemicals Corporation (South Africa) Revenue: by Geography 2019
  • Figure 49. Global Scopolamine: by Type USD Million (2020-2025)
  • Figure 50. Global Scopolamine: by Application USD Million (2020-2025)
  • Figure 51. Global Scopolamine: by Form USD Million (2020-2025)
  • Figure 52. Global Scopolamine: by Distribution Channel USD Million (2020-2025)
  • Figure 53. Global Scopolamine: by Side Effects USD Million (2020-2025)
  • Figure 54. South America Scopolamine Share (%), by Country
  • Figure 55. Asia Pacific Scopolamine Share (%), by Country
  • Figure 56. Europe Scopolamine Share (%), by Country
  • Figure 57. MEA Scopolamine Share (%), by Country
  • Figure 58. North America Scopolamine Share (%), by Country
  • Figure 59. Global Scopolamine: by Type K Tons (2020-2025)
  • Figure 60. Global Scopolamine: by Application K Tons (2020-2025)
  • Figure 61. Global Scopolamine: by Form K Tons (2020-2025)
  • Figure 62. Global Scopolamine: by Distribution Channel K Tons (2020-2025)
  • Figure 63. Global Scopolamine: by Side Effects K Tons (2020-2025)
  • Figure 64. South America Scopolamine Share (%), by Country
  • Figure 65. Asia Pacific Scopolamine Share (%), by Country
  • Figure 66. Europe Scopolamine Share (%), by Country
  • Figure 67. MEA Scopolamine Share (%), by Country
  • Figure 68. North America Scopolamine Share (%), by Country
  • Figure 69. Global Scopolamine: by Type USD/Units (2020-2025)
Some of the key companies/manufacturers profiled in the report
  • Baxter International Inc. (United States)
  • GlaxoSmithKline plc. Novartis AG (United Kingdom)
  • Perrigo Company plc. (Dublin)
  • Caleb Pharmaceuticals, Inc. (Taiwan)
  • Myungmoon Pharma Co. Ltd. (South Korea)
  • Alchem International (India)
  • Phytex Australia (Australia)
  • Centroflora Group (Brazil)
  • Alkaloids of Australia (Australia)
  • Fine Chemicals Corporation (South Africa)
Additional players considered in the study are as follows:
Vista Medical Ltd. (Canada) , Ohmatex ApS (Denmark)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation